News Releases

Keyword Search

Dec-11-2019
Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma
Dec-09-2019
Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting
Dec-03-2019
Oncternal Therapeutics to Present Cirmtuzumab Clinical Data Updates at 2019 ASH Annual Meeting and San Antonio Breast Cancer Symposium
Nov-21-2019
Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference
Nov-14-2019
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting
Nov-11-2019
Oncternal Therapeutics to Present at Stifel Healthcare Conference
Nov-07-2019
Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update
Nov-05-2019
Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting
Oct-31-2019
Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update
Oct-03-2019
Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma